Literature DB >> 6287193

Allosteric coupling between morphine and enkephalin receptors in vitro.

R B Rothman, T C Westfall.   

Abstract

In a recent paper from our laboratory [Mol. Pharmacol 21:538-547 (1982)] evidence was presented which suggested that [3H]leucine enkephalin labels a single class of binding sites (the enkephalin receptor) and that morphine allosterically induces a masking of enkephalin receptors as a consequence of binding to a receptor (the morphine receptor) not labeled by the 3H-peptide. Evidence is presented in this paper that [3H]etorphine can be used to label selectively the morphine receptor and that the inhibitory dissociation constants (KI) of morphine, etorphine, and human beta-endorphin for the [3H]etorphine binding site closely approximate the concentration of these drugs which produce a half-maximal decrease in the number of enkephalin receptors. Furthermore, an examination of the interaction of leucine enkephalin and methionine enkephalin with the morphine receptor has demonstrated that the pentapeptides are not competitive inhibitors of [3H] etorphine binding, and that they have much lower affinities for the morphine receptor than previously thought. On the basis of these data, a working hypothesis has been formulated which postulates that distinct morphine and enkephalin receptors coexist in an opioid-receptor complex.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287193

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

4.  ICI 174,864, a selective delta opioid antagonist, reverses the learning impairment produced by [leu]enkephalin.

Authors:  G Schulteis; J L Martinez
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Detailed analysis of heterogeneity of [3H]naloxone binding sites in rat brain synaptosomes.

Authors:  M Szücs; A Borsodi; A Bogdány; J Gaál; J Batke; G Tóth
Journal:  Neurochem Res       Date:  1987-07       Impact factor: 3.996

6.  Mathematical modeling of opiate binding to mouse brain membrane.

Authors:  H D Landahl; J Garzón; N M Lee
Journal:  Bull Math Biol       Date:  1985       Impact factor: 1.758

7.  Potentiation of pentazocine analgesia by low-dose naloxone.

Authors:  J D Levine; N C Gordon; Y O Taiwo; T J Coderre
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

8.  Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226.

Authors:  H Gicquiaux; M Tschöpl; H N Doods; B Bucher
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

9.  Interaction of naloxone with the opioid receptor complex in vitro.

Authors:  R B Rothman; T C Westfall
Journal:  Neurochem Res       Date:  1982-11       Impact factor: 3.996

10.  Multiple opioid receptors: an examination of the dissociation of [3H]leucine enkephalin from rat brain membranes.

Authors:  R B Rothman; T C Westfall
Journal:  Neurochem Res       Date:  1983-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.